Electra Therapeutics

Electra Therapeutics company information, Employees & Contact Information

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Company Details

Employees
32
Address
Complex And Difficult-To-Treat Diseases.
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Looking for a particular Electra Therapeutics employee's phone or email?

Electra Therapeutics Questions

News

Electra Therapeutics Announces $183 Million Series C - GlobeNewswire

Electra Therapeutics Announces $183 Million Series C GlobeNewswire

Electra Therapeutics' megaround runs counter to recent industry trend - San Francisco Business Times - The Business Journals

Electra Therapeutics' megaround runs counter to recent industry trend - San Francisco Business Times The Business Journals

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics - Cision News

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics Cision News

Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) - The Manila Times

Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) The Manila Times

Electra Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Electra Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference Business Wire

Electra Therapeutics Receives FDA Breakthrough Therapy and - GlobeNewswire

Electra Therapeutics Receives FDA Breakthrough Therapy and GlobeNewswire

Electra Therapeutics Presents Positive Clinical Results From Completed Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024 - Yahoo Finance

Electra Therapeutics Presents Positive Clinical Results From Completed Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024 Yahoo Finance

Electra Therapeutics secures $183m to fund Phase II/III trial of ELA026 - Clinical Trials Arena

Electra Therapeutics secures $183m to fund Phase II/III trial of ELA026 Clinical Trials Arena

Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) - Yahoo Finance

Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Yahoo Finance

'Some encouraging signs in the market': Electra shines with $183M fundraise for rare disease trial - Fierce Biotech

'Some encouraging signs in the market': Electra shines with $183M fundraise for rare disease trial Fierce Biotech

Electra Therapeutics raises US$183m in Series C financing - European Biotechnology Magazine

Electra Therapeutics raises US$183m in Series C financing European Biotechnology Magazine

Electra Therapeutics snags $183 million to target inflammatory diseases - Bizwomen - The Business Journals

Electra Therapeutics snags $183 million to target inflammatory diseases - Bizwomen The Business Journals

Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) - Yahoo Finance

Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) Yahoo Finance

ShopMy's $1.5b pitch, Electra Therapeutics' raise, and FalconX's buy - Axios

ShopMy's $1.5b pitch, Electra Therapeutics' raise, and FalconX's buy Axios

Series C - Electra Therapeutics - Crunchbase

Series C - Electra Therapeutics Crunchbase

Electra Therapeutics Raises $183M in Series C Funding - FinSMEs

Electra Therapeutics Raises $183M in Series C Funding FinSMEs

Electra Therapeutics: $183 Million Series C Raised To Advance SIRP-Targeted Therapies For Immune Disorders And Cancer - Pulse 2.0

Electra Therapeutics: $183 Million Series C Raised To Advance SIRP-Targeted Therapies For Immune Disorders And Cancer Pulse 2.0

ELA026 Shows Promise for Secondary HLH in Phase 1b Study - HCPLive

ELA026 Shows Promise for Secondary HLH in Phase 1b Study HCPLive

Electra Therapeutics, Inc. announced that it has received $183 million in funding from a group of investors - MarketScreener

Electra Therapeutics, Inc. announced that it has received $183 million in funding from a group of investors MarketScreener

Electra Therapeutics - The Pharma Letter

Electra Therapeutics The Pharma Letter

Electra Therapeutics appoints new chief executive - The Pharma Letter

Electra Therapeutics appoints new chief executive The Pharma Letter

Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer - Business Wire

Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer Business Wire

Electra, one of 2 Star biotechs, snags $84M to apply brakes to 'immune system haywire' - Fierce Biotech

Electra, one of 2 Star biotechs, snags $84M to apply brakes to 'immune system haywire' Fierce Biotech

Star Therapeutics Starts a Family with Electra - BioSpace

Star Therapeutics Starts a Family with Electra BioSpace

Electra Therapeutics Secures $183 Million Series C Funding for Immunology and Cancer Therapies - Global Legal Chronicle

Electra Therapeutics Secures $183 Million Series C Funding for Immunology and Cancer Therapies Global Legal Chronicle

Top Electra Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant